ESR1 and breast cancer: Compared with single Tamoxifen, or Fulvestrant, or Erastin treatment, the combination of the two drugs further inhibited the growth of ER+ breast cancer cells (Fig. 5I, S2B), indicating that inducing ferroptosis by targeting xc− can increase the sensitivity of ER+ breast cancer cells in response to endocrine therapy.